

## Trial of labor after cesarean and contribution of pelvimetry in the prognosis of neonatal morbidity

Nathalie Roux, Diane Korb, Cécile Morin, Olivier Sibony

### ▶ To cite this version:

Nathalie Roux, Diane Korb, Cécile Morin, Olivier Sibony. Trial of labor after cesarean and contribution of pelvimetry in the prognosis of neonatal morbidity. Journal of Gynecology Obstetrics and Human Reproduction, 2020, 49, pp.101681 -. 10.1016/j.jogoh.2020.101681 . hal-03490116

## HAL Id: hal-03490116 https://hal.science/hal-03490116

Submitted on 22 Aug 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

:
:

2 Trial of labor after cesarean and contribution of pelvimetry in the prognosis of neonatal

- 3 morbidity
- 4

#### 5 <u>Authors</u>:

- 6 Nathalie Roux<sup>1</sup>, Diane Korb<sup>1,2</sup>, Cécile Morin<sup>1</sup>, Olivier Sibony<sup>1</sup>
- 7

#### 8 Affiliations:

- <sup>9</sup> <sup>1</sup> Department of Obstetrics and Gynecology, Robert Debré Hospital, APHP, Paris, France
- <sup>2</sup> INSERM U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team
- 11 (EPOPé), Research Center for Epidemiology and Biostatistics Sorbonne Paris Cité (CRESS),
- 12 Université de Paris, F-75014, France

- 14 <u>Corresponding author:</u> Diane Korb, diane.korb@aphp.fr
- 15
- 16

- 17 Abstract
- 18

<u>Introduction</u>: To estimate the association between an abnormal pelvic dimension at
 pelvimetry and the occurrence of severe neonatal morbidity after trial of labor after cesarean
 (TOLAC).

22 Materials and Methods: Retrospective observational cases-controls study conducted at a 23 level 3 maternity units between 2006 and 2016. Included women were patient with trial of 24 labor after one previous cesarean section, alive singleton fetus in cephalic presentation  $\geq 37$ 25 WG. Two groups were compared according to pelvic mesures at pelvimetry: pelvic dimension 26 considered as abnormal, defined by Conjugate Diameter <10.5 cm and/or Transverse 27 Diameter <12 cm and pelvic dimension considered as normal for other women. The primary 28 outcome was a composite criterion of neonatal morbidity and mortality. A logistic 29 multivariate regression model was use to estimate the association between an abnormal pelvic 30 dimension at pelvimetry and the occurrence of severe neonatal morbidity

31 **<u>Results:</u>** 2474 women were included. 863 (34.8%) have a normal pelvic dimension and 1611 32 (65.2%) an abnormal. Characteristics of labor were similar in two groups. Success of 33 TOLAC was 84.7% in normal pelvic group and 64.6% in abnormal dimension of pelvic 34 group. Neonatal morbidity was similar between two groups (1.7% in normal pelvic dimension 35 group versus 2.3% in abnormal pelvic dimension group, p = 0.26; crude OR: 1.39 (0.77-36 2.49); adjusted OR : 0.93 (0.51-1.68)).

37 <u>Discussion:</u> There were no association between pelvic dimension at pelvimetry and neonatal
 38 morbidity. In case of abnormal pelvic dimension, a combination of more prudence, and
 39 stringent user practices, achieve a high rate of vaginal delivery and a neonatal morbidity
 40 comparable to the normal pelvic dimension group.

- 41
- 42 <u>Key-words :</u> Neonatal morbidity, Pelvimetry, Previous cesarean, Trial of labor after cesarean
   43 section (TOLAC)

#### 45 Introduction :

46 We observe an increase rate of women with previous cesarean delivery over the world [1,2,3]. 47 In France the rate of pregnant women with a history of cesarean delivery was 15.6% in 2010, 48 and 16.2% in 2016 [2]. For the labor management of women with previous cesarean delivery, 49 practionner can propose a planned iterative cesarean delivery or a planned vaginal delivery 50 [4]. The main feared complication of trial of labor after cesarean (TOLAC) is the occurrence 51 of uterine rupture because it is associated with an increased risk of maternal and neonatal 52 morbi-mortality [5,6]. Guidelines of developed countries encouraged TOLAC, because 53 cesarean delivery is associated with more neonatal and maternal complications at short and 54 long term, that increase with the number of cesareans, and because the risk of uterine rupture 55 is very sparse [7–10]. In case of previous cesarean, pelvimetry was studied for choosing the 56 mode of delivery, predicting the success of TOLAC and the occurrence of uterine rupture 57 [11]. Due to the absence of contribution of pelvimetry for decrease the failure of TOLAC and 58 for predict uterine rupture, the National College of French Gynecologists and Obstetricians 59 (CNGOF) conclude that the pelvimetry is not necessary for choosing the mode of delivery in 60 case of previous cesarean [4]. Despite these guidelines, actually in France, some practitioners 61 realize pelvimetry in case of previous cesarean, but the estimation of this practice was 62 difficult to determine. One study limited to the Northeast region estimated this practice at 63 44% of maternity units [11]. For practitioners maintaining the pelvimetry, it is not for 64 performing a planned cesarean delivery in case of abnormal dimension but for managing the 65 TOLAC according to the pelvic dimension associated with others clinical data (indication of 66 previous cesarean, estimated fetal weight, cervical dilatation...). Use of pelvimetry has been 67 poorly studied in case of TOLAC to evaluate its contribution in the management of labor and 68 in the neonatal prognosis.

69 The objective of this study was to estimate the association between an abnormal pelvic70 dimension at pelvimetry and the occurrence of severe neonatal morbidity after TOLAC.

71

#### 72 Materials and Methods:

73 It was a retrospective observational case-control study conducted at a level 3 maternity unit 74 between 2006 to 2016. The entire medical file was computerized and was completed 75 prospectively at each visit, at delivery, and during the post partum period. All data were 76 verified at the obstetrics staff meeting the day after the delivery. Inclusion criteria were 77 history of one previous cesarean delivery, with a planned vaginal delivery, with alive 78 singleton in cephalic presentation at or before 37 gestational age. Women were excluded if 79 they had two or more previous cesareans, an in utero fetal death before labor, a termination of 80 pregnancy, a fetal malformation, presentations other than cephalic, multiple pregnancies, 81 planned cesarean delivery. Women with missing data for the pelvimetry or the neonatal 82 outcomes were excluded.

83

We defined two study groups according to the pelvimetry : " pelvic dimension at pelvimetry considered as abnormal" defined by a transverse diameter (TD) < 12 cm, and/or conjugate diameter (CD) < 10.5 cm ; and "normal pelvic dimension at pelvimetry" for the other women. These cut offs were chosen because they are the usual cut off utilized [12-14].

88

All women with a previous cesarean whom delivered at this maternity, having a pelvimetry. The planned mode of delivery was discussed during the third trimester in meeting staff with the obstetrical team about obstetrical history, pelvimetry and estimated fetal weight. None cesarean delivery decision before labour was given on the pelvic components except for the pelvis, which was considered very abnormal (transverse diameter < 10.5 cm, and/or conjugate 94 diameter < 9.5 cm) [12-14]. Labor could be spontaneous, or induced in case of medical</li>
95 indication. There were no indication for cesarean delivery due to the absence of pelvimetry.

96 The use of oxytocine during labor was possible for medical indication. An arrest of labour at 97 two hours was autorized in case of uterine hypotonic dysfunction, beyond cesarean delivery 98 was recommanded. Internal tocometry was not used in this maternity unit, but to appreciate 99 uterin dynamic the use of an uterine palpation and vaginal examination was realized. In this 100 department, a routine manual uterine examination after delivery was performed to ensure the 101 integrity of the uterine scar. A uterine rupture was defined by complete rupture of the 102 myometrium and serosa. In case of uterine rupture, surgical revision by laparotomy was 103 considered only in cases of postpartum hemorrhage.

104

We collected the following data: the mothers' characteristics, any disease or disorders
occurring during pregnancy, characteristics of labor and delivery, any complications of
delivery, and neonatal characteristics.

108

109 The principal endpoint was a composite neonatal criterion, including at least one of following 110 items: per partum or neonatal death defined as death within 28 days after birth, hypoxic 111 ischemic encephalopathy defined as cerebral anomalies due to neonatal asphyxia (umbilical 112 pH < 7.0), Apgar score less than 4 at 5 min, endotracheal tube for more than 24h within 72h 113 after birth, or a proven neonatal sepsis defined as a positive hemoculture in the absence of any 114 other recognized etiology.

115 The secondary endpoint was the occurrence of uterine rupture.

116

117 Neonatal medical records were reviewed individually and completely for newborn's death,118 admitted to the NICU or neonatology unit.

119

120 We compared the characteristics of two groups based on Pearson's x2 test or Fisher exact test 121 for categorical variables, and Student t-test or Wilcoxon-Mann-Whitney test for quantitative 122 variables, as appropriate. Statistical significance was set at a two-tailed value of P.05. The 123 association between pelvic dimension at pelvimetry and severe neonatal morbidity was 124 analyzed with multivariable logistic regression. Causal assumptions between pelvic 125 dimension at pelvimetry, severe neonatal morbidity, and covariates were represented with a 126 directed acyclic graph to depict the exposure-outcome relations with confounding and intermediate factors (data not shown) for helping to select variables that are confounders (ie, 127 128 variables associated with both the exposure and the outcome) and those that do not qualify as 129 confounders (especially intermediate factors) [15]. The main regression model included only 130 the strict confounder: intra uterine growth restriction (IUGR).

131

132 The analyses were performed with Stata software version 13.0.

This database was approved by the National Data Protection Authority (Commission Nationale de l'Informatique et des Libertes, CNIL no. 293683). Under French regulations, this study was exempt from Institutional Review Board approval because it was an observational study using anonymized data from medical records. Women were informed that their records could be used for the evaluation of medical practices and were allowed to opt out of these studies.

139

#### 140 **<u>Results :</u>**

141 This study included 3083 women with a previous cesarean and with alive singleton in 142 cephalic presentation at or after 37 gestational age (GA). We excluded 54 (1.7%) women with 143 a fetus with a congenital malformation and 208 (6.7%) with planned cesarean delivery. Data for pelvimetry were missing for 270 (8.7%) women, and neonatal data were missing for 77
(2.5%) newborn (Figure 2). Thus, 2474 women were included in this analysis.

Among included women, 1611 (65%) having a normal pelvic dimension at pelvimetry and 863 (35%) an abnormal dimension. Transverse diameter was less than 12 cm for 771 (31,2%) women, whose 418 (16,9%) with a transverse diameter less than 11,5 cm. Conjugate diameter was less than 10,5cm for 252 (10,2%) women, whose 70 (2,8%) with a conjugate diameter less than 10 cm. Among women with abnormal dimension, 160/863 (18.5%) women had both a transverse diameter < 12 and a conjugate diameter <10.5.

152

153 Compared with women with normal pelvic dimension at pelvimetry, women with abnormal 154 pelvic dimension were more statistically younger (32.9 years vs 33.5 years; p = 0.01) and 155 have less weight gain during pregnancy (10.3 kg vs 11.2 kg; p < 0.01), without these 156 differences were clinically pertinent. There was no difference between the two groups for 157 body mass index and parity.

158 Compared with women with normal pelvic dimension at pelvimetry, women with abnormal 159 pelvic dimension have less previous vaginal birth after cesarean delivery (23.4% vs 28.6%; p 160 < 0.01), more gestational hypertensive pathology (5% vs 3%; p = 0.01) and more suspected 161 IUGR (1.6% vs 0.7% p=0.02) (Table 1).

162 No significant difference was found between the two groups regarding delivery term, onset of
163 labor, methods of labor induction, analgesia, duration of labor and use of oxytocin during
164 labor (Table 2).

165 Compared with women with normal pelvic dimension at pelvimetry, women with abnormal
166 pelvic dimension have more cesarean delivery during labor (35.3% vs 15.2%; p < 0.01).</li>

167 The rate of abnormal fetal heart rate (FHR), requiring cesarean delivery or instrumental168 delivery, was higher in abnormal pelvic dimension group.

169 No significant difference was found between the two groups regarding uterine dehiscence,170 uterine rupture, and postpartum hemorrhage. There was no maternal death.

171 In abnormal pelvic dimension at pelvimetry group, 8 uterine ruptures occurs (0.8%). In 172 normal pelvic dimension at pelvimetry group, 10 uterine ruptures occurs (0.6%). Among the 173 18 uterine ruptures, 16 had an emergency cesarean for suspected uterine rupture and two had 174 instrumental vaginal delivery for abnormal FHR and the diagnostic of uterine rupture was 175 realized during the manual uterine examination and was required a surgery for post partum 176 hemorrhage.

177 Neonatal morbidity was similar between the two groups (2.3% versus 1.7%, p = 0.26; crude178 OR : 1.39 (0.77-2.49) ; adjusted OR: 0.93 (0.51-1.68)) (Table 4).

In abnormal pelvic dimension at pelvimetry group, one neonatal death occurs due to hypoxic ischemic encephalopathy within 2 days after birth. It was an emergency cesarean delivery due to uterine rupture. In normal pelvic dimension at pelvimetry group, one neonatal death occurs due to hypoxic ischemic encephalopathy after cardiac failure (dilated cardiomyopathy). It was not detected on antenatal sonography. In the same group, the second cases with hypoxic ischemic encephalopathy was due to respiratory distress (endotracheal tube for more than 24h within 72h after birth) after an emergency cesarean for uterine rupture.

186

187

188

189

#### 190 Discussion :

Based on this population of women with trial of labor after one previous cesarean delivery,
we showed that abnormal pelvic dimension at pelvimetry was not associated with an
increased neonatal morbidity.

194

195 Our study has some strenghts. Data were valid and exhaustive because they were collected 196 prospectively through computer software used by all medical staff and verified every morning 197 during collegial meeting, and for severe events such as uterine rupture, and neonatal 198 morbidity, all medical record were analyzed. We used a severe composite neonatal criteria 199 approved in many studies [16,17]. This primary outcome is pragmatic and logical, and it has 200 good external validity. Due to the unicentric characteristic of this study, obstetrical practices 201 were uniform in the management of patients during labor, for prenatal care and for the 202 decision of cesarean.

203

Extrapolation of our results is limited since the study was conducted in a single center, realizing more than three thousands of delivery by year with a cesarean delivery rate lower than nationally rate. A limitation of this study was the pelvimetry cut-off value to define "abnormal pelvic". These cut-offs, although in common use, may have some limitations. Their determinations are old, and little documented. With stricter limit value, we would have decrease number of cases, and decrease study strength. Nevertheless it was pelvimetry cut-off value frequently used in French maternity [18].

211

212 The approach of this study was descriptive for having pragmatic results, and not explicative.

Some hypothesis could have suggested a negative impact on neonatal outcomes of abnormalpelvic dimension. Duration of labor more longer, abnormal FHR more frequent and

215 instrumental vaginal delivery more complex are feared in case of trial of labor and abnormal 216 pelvic dimension, with in case of obstetrical complications, a possible neonatal resounding. 217 This was not found in our study not showing any difference in neonatal outcome according to 218 pelvic dimension. It was an original result because it is the first study analyzing the 219 association between dimension of pelvis and neonatal morbidity. Previously, some studies 220 analyzed maternal outcomes (like uterine rupture) and obstetrical outcomes (like the rate of 221 cesarean delivery) in case of TOLAC. An impact of pelvic dimension on neonatal morbidity 222 would have been interesting to adapt pediatric management at the birth and prevent some 223 critical situations.

224

Although the neonatal morbidity was similar in two groups of pelvic dimension, we found more abnormal FHR in abnormal pelvic dimension group. This could be explained by a different fetal head compression during its confrontation with the maternal pelvis during uterine contractions and expulsive efforts. Despite this abnormal FHR, neonatal morbidity was similar. It is possible that this is due to increased vigilance of the team who intervene quickly during labor for abnormal FHR or arrest of cervical dilatation, because of the knowledge of the pelvic dimension.

232

In accordance with literature, we showed that cesarean delivery rate was higher in case of abnormal pelvic dimension [13,19]. Due to the observational design of this study, an indication bias could not be excluded and explained this increased rate of cesarean delivery in the group of women with abnormal pelvic dimension. Indeed, all practitioners know the pelvic dimension, which may have influenced their decisions to realize a cesarean delivery for less strict indications in abnormal pelvic dimension group. However, global cesarean delivery rate in our study (22%) was lower than many studies (from 20 to 40%) [7,9]. It is fair to confirm, in accordance with French guidelines, that pelvimetry should not have to use in planning mode of delivery. Thus the practice of pelvimetry does not necessarily cause an increased rate of cesarean delivery. The practice of such a complementary examination must be considered and the results adapted. The fear of increasing the rate of cesarean delivery because of the only realization of the pelvimetry does not seem to justify and is questioned.

The rate of uterine rupture was low (0.7%), similar with results of literature [20,21]. In this study, uterine rupture was not associated with pelvic dimension, but it was not the main endpoint and the power of this study is smaller to highlight a difference concerning the occurrence of such a rare event.

249 In conclusion, there was no association between pelvic dimension at pelvimetry and neonatal 250 morbidity. This result does not question the recommendation on the pelvimetry for women 251 with previous cesarean delivery, and obstetrical team realizing pelvimetry for this indication 252 will probably continue its practice. For women with abnormal pelvic dimension, a 253 combination of more prudence, and stringent user practices, can allow to achieve a high rate 254 of vaginal delivery and a neonatal morbidity comparable to the normal pelvic dimension 255 group. A further study, on the specific contribution of pelvimetry in the management of labor 256 in case of TOLAC, cannot be conducted by a retrospective design, should be conducted 257 prospectively.

258

259 **Disclosure of interests:** The authors report no conflict of interest

260 <u>Acknowledgments:</u> Not applicable

261 **Funding :** Not applicable

262 <u>Authors contribution:</u> NR contributions were the acquisition of data, analysis and
263 interpretation of data, drafting the article and final approval of the version to be submitted.


DK contributions were the conception and design of the study, analysis and interpretation of data, drafting the article and final approval of the version to be submitted. CM contributions were the analysis and interpretation of data, revising the article critically for important intellectual content, and final approval of the version to be submitted. OS contributions were the conception and design of the study, analysis and interpretation of data, revising the article critically for important intellectual content, and final approval of the version to be submitted. 270 <u>Références :</u>

- [1] Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Drake P. Births: Final data for
  2016. National Vital Statistics Reports; vol 67 no 1. Hyattsville, MD: National Center for
  Health Statistics. 2018.
- [2] Blondel B, Lelong N, Kermarrec M, Goffinet F, National Coordination Group of the
  National Perinatal Surveys. Trends in perinatal health in France from 1995 to 2010. Results
  from the French National Perinatal Surveys. J Gynecol Obstet Biol Reprod (Paris). 2012
  Jun;41(4):e1–15.
- [3] http://www.europeristat.com/images/EPHR2015\_Euro-Peristat.pdf.
- 279 [4] Sentilhes L, Vayssière C, Beucher G, Deneux-Tharaux C, Deruelle P, Diemunsch P, et al.
- 280 Delivery for women with a previous cesarean: guidelines for clinical practice from the French
- 281 College of Gynecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol.
  282 2013 Sep;170(1):25–32.
- [5]. Landon MB, Hauth JC, Leveno KJ, Spong CY, Leindecker S, Varner MW, et al.
  Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery.
  N Engl J Med. 2004 Dec 16;351(25):2581–9.
- [6]. Vandenberghe G, Bloemenkamp K, Berlage S, Colmorn L, Deneux-Tharaux C,
  Gissler M, et al. The International Network of Obstetric Survey Systems study of uterine
  rupture: a descriptive multi-country population-based study. BJOG Int J Obstet Gynaecol.
  2018 May 4;
- 290 [7]. American College of Obstetricians and Gynecologists. ACOG Practice bulletin no.
  291 115: Vaginal birth after previous cesarean delivery. Obstet Gynecol. 2010 Aug;116(2 Pt
  292 1):450–63.
- 293 [8]. Birth after Previous Caesarean Birth (Green-top Guideline No. 45). Royal College of
  294 Obstetricians & amp; Gynaecologists. 2017 Aug.
  - 13

- [9]. Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice
  guidelines. Guidelines for vaginal birth after previous caesarean birth. Number 155. Int J
  Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2005 Jun;89(3):319–31.
- [10]. ACOG Committee Opinion No. 761: Cesarean Delivery on Maternal Request. Obstet
  Gynecol. 2019 Jan;133(1):e73–7.
- 300 [11]. Sataf R, Gauchotte E, Muhlstein J, Bernard C, Gauchotte G, Morel O. X-ray
  301 pelvimetry practice survey in Northeast French maternities. J Gynecol Obstet Biol Reprod
  302 (Paris). 2015 Mar;44(3):252–7.
- 303 [9]. Sentilhes L, Vayssière C, Beucher G, Deneux-Tharaux C, Deruelle P, Diemunsch P, et
- 304 al. Delivery for women with a previous cesarean: guidelines for clinical practice from the
- French College of Gynecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod
   Biol. 2013 Sep;170(1):25–32.
- 307 [12]. Barron LR, Hill RO, Linkletter AM. X-RAY PELVIMETRY. Can Med Assoc J. 1964
  308 Dec 5;91:1209–12.
- 309 [13]. Thubisi M, Ebrahim A, Moodley J, Shweni PM. Vaginal delivery after previous
  310 caesarean section: is X-ray pelvimetry necessary? Br J Obstet Gynaecol. 1993
  311 May;100(5):421–4.
- 312 [14] Maharaj D. Assessing cephalopelvic disproportion: back to the basics. Obstet Gynecol
  313 Surv. 2010 Jun;65(6):387–95.
- 314 [15]. Ananth CV, Schisterman EF. Confounding, causality, and confusion: the role of
  315 intermediate variables in interpreting observational studies in obstetrics. Am J Obstet
  316 Gynecol. 2017;217(2):167–75.
- 317 [16]. Barrett JFR, Hannah ME, Hutton EK, Willan AR, Allen AC, Armson BA, et al. A
  318 randomized trial of planned cesarean or vaginal delivery for twin pregnancy. N Engl J Med.
  319 2013 Oct 3;369(14):1295–305.

- 320 [17]. Schmitz T, Korb D, Battie C, Cordier A-G, de Carne Carnavalet C, Chauleur C, et al.
  321 Neonatal morbidity associated with vaginal delivery of noncephalic second twins. Am J
  322 Obstet Gynecol. 2018 Apr;218(4):449.e1-449.e13.
- 323 [18]. Bourdon M, Ceccaldi PF, Girard G, Koskas M, Goffinet F, Le Ray C. Inter-observer
  324 variability of decision concerning the route of delivery in case of one previous cesarean
  325 section and abnormal pelvic measures. J Gynecol Obstet Biol Reprod (Paris). 2016
  326 Nov;45(9):1172–8.
- 327 [19]. Sibony O, Alran S, Oury J-F. Vaginal birth after cesarean section: X-ray pelvimetry at
  328 term is informative. J Perinat Med. 2006;34(3):212–5.
- 329 [20]. Al-Zirqi I, Stray-Pedersen B, Forsén L, Daltveit A-K, Vangen S. Uterine rupture:
  330 trends over 40 years. BJOG Int J Obstet Gynaecol. 2016 Apr;123(5):780–7.
- 331 [21]. Beucher G, Dolley P, Lévy-Thissier S, Florian A, Dreyfus M. Maternal benefits and
  332 risks of trial of labor versus elective repeat caesarean delivery in women with a previous
  333 caesarean delivery. J Gynecol Obstet Biol Reprod (Paris). 2012 Dec;41(8):708–26.
- 334
- 335

#### 338 Figure 1 : Flow Chart



#### 343 Table 1: Maternal and obstetrical characteristics

Maternal age (mean $\pm$ SD) < 30 (30-39) $\geq$ 40 Body mass index < 18.5 (18.5-24) (25-29) $\geq$ 30 Weight gain (mean $\pm$ SD) Previous medical conditions Hypertensive pathology Preexisting diabetes at pregnancy Parity 2 $\geq$ 3 Previous pregnancy-related disease Gestational hypertensive pathology	$\begin{array}{r} \text{mension at pelvimetry} \\ n=863 \\ \hline N (\%) \\ \hline 32.9 \pm 5.1 \\ 252 (29.2) \\ 546 (63.3) \\ 65 (7.5) \\ 25.4 \pm 5.3 \\ 37 (4.3) \\ 363 (42.1) \\ 248 (28.6) \\ 151 (17.5) \\ 10.3 \pm 6.1 \\ \hline 30 (3.5) \\ 13 (1.5) \end{array}$	dimension at pelvimetry n=1611 N (%) $33.5 \pm 5$ 426 (26.4) 1019(63.3) 166 (10.3) $25.2\pm5.37$ 89 (5.5) 696 (43.2) 431 (26.8) 295 (18.3) $11.2\pm5.9$ 55 (3.4)	0.01 0.04 0.24 < 0.0 <sup>2</sup>
<pre>&lt; 30 (30-39) <math>\geq</math> 40 Body mass index &lt; 18.5 (18.5-24) (25-29) <math>\geq</math> 30 Weight gain (mean ± SD) Previous medical conditions Hypertensive pathology Preexisting diabetes at pregnancy Parity 2 <math>\geq</math> 3 Previous pregnancy-related disease Gestational hypertensive pathology</pre>	N (%) $32.9 \pm 5.1$ 252 (29.2) 546 (63.3) 65 (7.5) $25.4 \pm 5.3$ 37 (4.3) 363 (42.1) 248 (28.6) 151 (17.5) $10.3 \pm 6.1$ 30 (3.5)	N (%) $33.5 \pm 5$ 426 (26.4) 1019(63.3) 166 (10.3) $25.2\pm 5.37$ 89 (5.5) 696 (43.2) 431 (26.8) 295 (18.3) $11.2\pm 5.9$ 55 (3.4)	0.04 0.24 < 0.0
<pre>&lt; 30 (30-39) <math>\geq</math> 40 Body mass index &lt; 18.5 (18.5-24) (25-29) <math>\geq</math> 30 Weight gain (mean ± SD) Previous medical conditions Hypertensive pathology Preexisting diabetes at pregnancy Parity 2 <math>\geq</math> 3 Previous pregnancy-related disease Gestational hypertensive pathology</pre>	$\begin{array}{c} 32.9 \pm 5.1 \\ 252 (29.2) \\ 546 (63.3) \\ 65 (7.5) \\ 25.4 \pm 5.3 \\ 37 (4.3) \\ 363 (42.1) \\ 248 (28.6) \\ 151 (17.5) \\ 10.3 \pm 6.1 \\ 30 (3.5) \end{array}$	$\begin{array}{c} 33.5 \pm 5 \\ 426 \ (26.4) \\ 1019 \ (63.3) \\ 166 \ (10.3) \\ 25.2 \pm 5.37 \\ 89 \ (5.5) \\ 696 \ (43.2) \\ 431 \ (26.8) \\ 295 \ (18.3) \\ 11.2 \pm 5.9 \\ 55 \ (3.4) \end{array}$	0.04 0.24 < 0.0
<pre>&lt; 30 (30-39) <math>\geq</math> 40 Body mass index &lt; 18.5 (18.5-24) (25-29) <math>\geq</math> 30 Weight gain (mean ± SD) Previous medical conditions Hypertensive pathology Preexisting diabetes at pregnancy Parity 2 <math>\geq</math> 3 Previous pregnancy-related disease Gestational hypertensive pathology</pre>	252 (29.2) 546 (63.3) 65 (7.5) 25.4±5.3 37 (4.3) 363 (42.1) 248 (28.6) 151 (17.5) 10.3±6.1 30 (3.5)	426 (26.4) 1019(63.3) 166 (10.3) 25.2±5.37 89 (5.5) 696 (43.2) 431 (26.8) 295 (18.3) 11.2±5.9 55 (3.4)	0.04 0.24 < 0.0
(30-39) $\geq 40$ Body mass index < 18.5 (18.5-24) (25-29) $\geq 30$ Weight gain (mean ± SD) Previous medical conditions Hypertensive pathology Preexisting diabetes at pregnancy Parity 2 $\geq 3$ Previous pregnancy-related disease Gestational hypertensive pathology	546 (63.3) 65 (7.5) 25.4±5.3 37 (4.3) 363 (42.1) 248 (28.6) 151 (17.5) 10.3±6.1 30 (3.5)	1019(63.3) 166 (10.3) 25.2±5.37 89 (5.5) 696 (43.2) 431 (26.8) 295 (18.3) 11.2±5.9 55 (3.4)	0.24 < 0.0 <sup>-</sup>
≥ 40 Body mass index < 18.5 (18.5-24) (25-29) ≥ 30 Weight gain (mean ± SD) Previous medical conditions Hypertensive pathology Preexisting diabetes at pregnancy Parity 2 ≥ 3 Previous pregnancy-related disease Gestational hypertensive pathology	65 (7.5) 25.4±5.3 37 (4.3) 363 (42.1) 248 (28.6) 151 (17.5) 10.3±6.1 30 (3.5)	166 (10.3) 25.2±5.37 89 (5.5) 696 (43.2) 431 (26.8) 295 (18.3) 11.2±5.9 55 (3.4)	< 0.0
Body mass index < 18.5 (18.5-24) (25-29) $\geq$ 30 Weight gain (mean ± SD) Previous medical conditions Hypertensive pathology Preexisting diabetes at pregnancy Parity 2 $\geq$ 3 Previous pregnancy-related disease Gestational hypertensive pathology	25.4±5.3 37 (4.3) 363 (42.1) 248 (28.6) 151 (17.5) 10.3±6.1 30 (3.5)	25.2±5.37 89 (5.5) 696 (43.2) 431 (26.8) 295 (18.3) 11.2±5.9 55 (3.4)	< 0.0
<ul> <li>&lt; 18.5 <ul> <li>(18.5-24)</li> <li>(25-29)</li> <li>≥ 30</li> </ul> </li> <li>Weight gain (mean ± SD)</li> <li>Previous medical conditions <ul> <li>Hypertensive pathology</li> <li>Preexisting diabetes at pregnancy</li> </ul> </li> <li>Parity <ul> <li>2</li> <li>≥ 3</li> </ul> </li> <li>Previous pregnancy-related disease <ul> <li>Gestational hypertensive pathology</li> </ul> </li> </ul>	25.4±5.3 37 (4.3) 363 (42.1) 248 (28.6) 151 (17.5) 10.3±6.1 30 (3.5)	89 (5.5) 696 (43.2) 431 (26.8) 295 (18.3) 11.2±5.9 55 (3.4)	< 0.0
<pre>(18.5-24) (25-29) ≥ 30 Weight gain (mean ± SD) Previous medical conditions Hypertensive pathology Preexisting diabetes at pregnancy Parity 2 ≥ 3 Previous pregnancy-related disease Gestational hypertensive pathology</pre>	363 (42.1) 248 (28.6) 151 (17.5) 10.3±6.1 30 (3.5)	696 (43.2) 431 (26.8) 295 (18.3) 11.2±5.9 55 (3.4)	
(25-29) $\geq 30$ Weight gain (mean ± SD) Previous medical conditions Hypertensive pathology Preexisting diabetes at pregnancy Parity 2 $\geq 3$ Previous pregnancy-related disease Gestational hypertensive pathology	248 (28.6) 151 (17.5) 10.3±6.1 30 (3.5)	431 (26.8) 295 (18.3) 11.2±5.9 55 (3.4)	
<ul> <li>(25-29)</li> <li>≥ 30</li> <li>Weight gain (mean ± SD)</li> <li>Previous medical conditions</li> <li>Hypertensive pathology</li> <li>Preexisting diabetes at pregnancy</li> <li>Parity</li> <li>2</li> <li>≥ 3</li> <li>Previous pregnancy-related disease</li> <li>Gestational hypertensive pathology</li> </ul>	248 (28.6) 151 (17.5) 10.3±6.1 30 (3.5)	431 (26.8) 295 (18.3) 11.2±5.9 55 (3.4)	
<ul> <li>≥ 30</li> <li>Weight gain (mean ± SD)</li> <li>Previous medical conditions         <ul> <li>Hypertensive pathology</li> <li>Preexisting diabetes at pregnancy</li> </ul> </li> <li>Parity         <ul> <li>2</li> <li>≥ 3</li> </ul> </li> <li>Previous pregnancy-related disease             Gestational hypertensive pathology</li> </ul>	151 (17.5) 10.3±6.1 30 (3.5)	295 (18.3) 11.2±5.9 55 (3.4)	
Previous medical conditions Hypertensive pathology Preexisting diabetes at pregnancy Parity 2 ≥ 3 Previous pregnancy-related disease Gestational hypertensive pathology	10.3±6.1 30 (3.5)	11.2±5.9 55 (3.4)	
Previous medical conditions Hypertensive pathology Preexisting diabetes at pregnancy Parity 2 ≥ 3 Previous pregnancy-related disease Gestational hypertensive pathology	30 (3.5)	55 (3.4)	
Hypertensive pathology Preexisting diabetes at pregnancy Parity 2 ≥ 3 Previous pregnancy-related disease Gestational hypertensive pathology			0.00
Preexisting diabetes at pregnancy Parity 2 ≥ 3 Previous pregnancy-related disease Gestational hypertensive pathology			0.93
Parity 2 ≥ 3 Previous pregnancy-related disease Gestational hypertensive pathology		29 (1.8)	0.59
2 ≥ 3 Previous pregnancy-related disease Gestational hypertensive pathology			0.59
≥ 3 Previous pregnancy-related disease Gestational hypertensive pathology	512 (60.0)	929 (58.0)	
Previous pregnancy-related disease Gestational hypertensive pathology	351 (40.0)	682 (42.0)	
Gestational hypertensive pathology		001 (11.0)	
	64 (7.0)	141 (9.0)	0.25
Gestational diabetes	53 (6.1)	112 (7.0)	0.44
Shoulder dystocia	24 (2.8)	29 (1.8)	0.10
Vaginal delivery after cesarean	202 (23.4)	460 (28.6)	0.00
delivery	202 (20:1)	100 (20.0)	0.00
Pregnancy-related disease			
Gestational hypertensive pathology	46 (5.0)	52 (3.0)	0.01
Gestational diabetes	70 (8.1)	120 (7.4)	0.55
Preterm labour	22 (2.5)	44 (2.7)	0.79
Premature ruptur of membranes	3 (0.3)	2 (0.1)	0.23
Suspected IUGR	14 (1.6)	11 (0.7)	0.02

#### **Table 2: Labor characteristics**

	Abnormal pelvic dimension at pelvimetry n = 863	Normal pelvic dimension at pelvimetry n = 1611	р
	N (%)	N (%)	
Gestational age at delivery			0.11
(37-38)	155 (18.0)	303 (18.8)	
(39-40)	525 (60.8)	911 (56.5)	
41	156 (18.1)	324 (20.1)	
≥ 42	27 (3.1)	73 (4.5)	
Spontaneous labour	656 (76.0)	1199 (74.4)	0.38
Induced labour	207 (24.0)	412 (25.6)	
Ocytocine	57 (27.0)	94 (23.0)	0.15
Intracervical prostaglandin	150 (73.Ó)	318 (77.Ó)	
Intracervical prostaglandin and	9 (7.0)	48 (15.0)	0.08
misoprostol		(	
Peridural analgesia	785 (91.0)	1434 (89)	0.12
Artificial rupture of membranes	432 (50.1)	797 (49.5)	0.37
Labour duration (min) (mean $\pm$ SD)	380 ± 216	369 ± 208	0.28
Median (Q1-Q3)	374 (223-516)	350 (287-507.5)	
Use of ocytocine	516 (59.8)	948 (58.8)	0.80
Max dose (median (Q1-Q3))	40 (20-60)	40 (20-50)	0.75
Duration (min) mean+/-SD	51 ±100	45 ±103	0.17
Arrest of labour	145 (16.8)	286(17.8)	0.55
Clinical estimated fetal weight (mean ± SD)	3374 ± 369	3393 ± 384	0.23

# 378379 Table 3: Delivery characteristics

	Abnormal pelvic dimension at pelvimetry	Normal pelvic dimension at pelvimetry	р
	n = 863	n = 1611	
Mode of delivery	N (%)	N (%)	< 0.001
Cesarean	305 (35.3)	245 (15.2)	<0.00
Vaginal delivery	558 (64.7)	1366 (84.8)	
Cesarean	000 (04.7)	1000 (04.0)	0.26
Indication			0.20
Fetal*	118 (38.6)	107 (43.6)	
Maternal**	6 (0.6)	8 (3.4)	
Obstetrical***	181 (59.3)	130 (53.0)	
Vaginal delivery			
Spontaneous	366 (66.0)	905 (66.0)	0.97
İnstrumental	192 (34.0)́	461 (34.0)́	
Indication	× ,	( , , , , , , , , , , , , , , , , , , ,	<0.00
FHR anormalies	142 (74.0)	260 (57.0)	
Default of progression	50 (26.0)	201 (43.0)	
Shoulder dystocia	10 (1.2)	8 (0.5)	0.06
Uterine scar			
Dehiscence scar	20 (2.3)	40 (2.5)	0.79
Uterine rupture	8 (0.9)	10 (0.6)	0.24
Postpartum hemorhage	48 (5.0)	90 (5.0)	0.37
Embolization	0	1 (0.1)	
Hysterectomy	0	0	
Ligature	0	1 (0.1)	
Transfusion	10 (1.2)	16 (1.0)	
Sulprostone	28 (3.2)	63 (4.0)	
Capitonnage	0	3 (0.2)	
Bakri balloon	0	2(0.1)	

380 \*abnormal FHR

381 \*\*preeclampsia, HELLP syndrom

82 \*\*\*arrest of labor, failure of induced labor

#### 384 Table 4: Neonatal outcomes

\*adjusted for IUGR

	Abnormal pelvic dimension at pelvimetry n=863 N (%)	Normal pelvic dimension at pelvimetry n=1611 N (%)	р	OR	aOR*
Composite criteria	20 (2.3)	27 (1.7)	0.26	1.39 (0.77-2.49)	0.93 (0.51-1.68)
Neonatal death	1 (0.1)	1 (0.1)	0.65	· · · · · · · · · · · · · · · · · · ·	, , , , , , , , , , , , , , , , , , ,
Hypoxic ischemic	2 (0.2)	1 (0.1)	0.25		
Encéphalopathy	(				
5-min Apgar score < 4	6 (0.7)	4 (0.2)	0.09		
Materno-fetal infection	6 (0.7)	14 (0.9)	0.64		
Intubation > 24H	10 (1.2)	10 (0.7)	0.15		
umbilical pH < 7.10	40 (4.6)	29 (1.8)	< 0.001		
umbilical pH < 7.0	10 (1.2)	8 (0.5)	0.16		
Birth weight in grams (mean±SD)	3322±428	3460±498	< 0.001		
<2500 grams	26 (3.0)	43 (2.7)	0.62		
≥ 4500 grams	3 (0.3)	32 (2.0)	0.001		